Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820537 | 1.00 | FOLH1 (0.45) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL6372184 | 0.84 | FOLH1 (0.47) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL2818361 | 0.83 | KIF11 (0.43) | KIF11 | |
| SCHEMBL2818358 | 0.83 | KIF11 (0.43) | KIF11 | |
| SCHEMBL2814403 | 0.81 | FABP5 (0.39) | KIF11 | |
| SCHEMBL11306029 | 0.80 | FOLH1 (0.49) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL24447455 | 0.79 | CTSK (0.51) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL28404302 | 0.79 | FOLH1 (0.63) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL25183100 | 0.79 | CTSK (0.51) | FOLH1ITGB3ITGA2BABCB1CTSL | |
| SCHEMBL7087077 | 0.79 | FOLH1 (0.63) | FOLH1ITGB3ITGA2BABCB1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1444194-B1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | CIS BIO INT (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1444194-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003042163-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | BHMT, BHMT2, AHCY | FOLH1 204/4885ITGB3 4193/4885ITGA2B 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.